Abivax presents first quarter 2025 financial results

Abivax presents first quarter 2025 financial results paris, france, june 2, 2025, 10:00 p.m. cest – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq – abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended march 31, 2025.
ABVX Ratings Summary
ABVX Quant Ranking